Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-130.15	275.19	-78.96	-127.39	-125.55
Depreciation & Amortization	1.28	2.9	3.31	3.37	2.78
Loss (Gain) From Sale of Investments	-7.22	-8.88	-4.57	-0.55	1.83
Stock-Based Compensation	45.97	37.55	29.29	24.2	16.4
Other Operating Activities	1.58	-	0.19	-	-
Change in Accounts Receivable	164.88	-155	-9.99	1.56	0.86
Change in Accounts Payable	3.72	0.84	-2.87	2.05	-1.39
Change in Unearned Revenue	-21.02	30.57	-	-1.6	-12.88
Change in Income Taxes	-2.69	2.69	-	-	-
Change in Other Net Operating Assets	1.31	-1.71	-6.65	-9.77	10.09
Operating Cash Flow	57.67	184.15	-70.24	-108.14	-107.87
Operating Cash Flow Growth	-68.68%	-	-	-	-
Capital Expenditures	-1.59	-1.36	-0.61	-0.8	-1.1
Investment in Securities	-47.74	-298.13	-38.65	92.26	-14.76
Investing Cash Flow	-49.33	-299.48	-39.26	91.47	-15.86
Issuance of Common Stock	23.34	26.45	171.25	19	130.11
Repurchase of Common Stock	-0.48	-0.6	-0.77	-0.19	-0.19
Other Financing Activities	-	-	-	0.03	-
Financing Cash Flow	22.86	25.85	170.48	18.84	129.92
Foreign Exchange Rate Adjustments	-	-	-	-0.09	-0.13
Net Cash Flow	31.2	-89.48	60.98	2.08	6.07
Free Cash Flow	56.08	182.8	-70.85	-108.93	-108.97
Free Cash Flow Growth	-69.32%	-	-	-	-
Free Cash Flow Margin	121.87%	42.08%	-118.08%	-409.81%	-398.31%
Free Cash Flow Per Share	0.88	2.81	-1.25	-2.22	-2.35
Cash Income Tax Paid	3.69	1.53	-	-	-
Levered Free Cash Flow	105.62	65.11	-43.31	-60.37	-61.59
Unlevered Free Cash Flow	105.62	65.11	-43.31	-60.37	-61.59
Change in Working Capital	146.21	-122.61	-19.51	-7.77	-3.31

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q